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Abstract
BACKGROUND: Kentucky ranks first in the US in cancer incidence and mortality. Compounded 
by high poverty levels and a high rate of medically uninsured, cancer rates are even worse in 
Appalachian Kentucky. Being one of the first states to adopt the Affordable Care Act (ACA) 
Medicaid expansion, insurance coverage markedly increased for Kentucky residents. The purpose 
of our study was to determine the impact of Medicaid expansion on colorectal cancer (CRC) 
screening, diagnosis, and survival in Kentucky.
STUDY DESIGN: The Kentucky Cabinet for Health and Family Services and the Kentucky 
Cancer Registry were queried for individuals (≥20 years old) undergoing CRC screening (per US 
Preventative Services Task Force) or diagnosed with primary invasive CRC from January 1, 2011 
to December 31, 2016. Colorectal cancer screening rates, incidence, and survival were compared 
before (2011 to 2013) and after (2014 to 2016) ACA implementation.
RESULTS: Colorectal cancer screening was performed in 930,176 individuals, and 11,441 new 
CRCs were diagnosed from 2011 to 2016. Screening for CRC increased substantially for Medicaid 
patients after ACA implementation (+230%, p < 0.001), with a higher increase in screening among 
the Appalachian (+44%) compared with the non-Appalachian (+22%, p < 0.01) population. The 
incidence of CRC increased after ACA implementation in individuals with Medicaid coverage 
(+6.7%, p < 0.001). Additionally, the proportion of early stage CRC (stage I/II) increased by 9.3% 
for Appalachians (p = 0.09), while there was little change for non-Appalachians (−1.5%, p = 0.60). 
Colorectal cancer survival was improved after ACA implementation (hazard ratio 0.73, p < 0.01), 
particularly in the Appalachian population with Medicaid coverage.
CONCLUSIONS: Implementation of Medicaid expansion led to a significant increase in CRC 
screening, CRC diagnoses, and overall survival in CRC patients with Medicaid, with an even more 
profound impact in the Appalachian population.
Kentucky ranks first nationally in incidence and mortality of all site cancers.1,2 The 
Appalachian region of Kentucky heavily contributes to these poor outcomes, where cancer 
surpasses heart disease as the leading cause of death.2,3 The etiology of the 
disproportionately high cancer rate is multifaceted, but a major factor is the distressed 
socioeconomic status in Kentucky.2 For the past decade, Kentucky maintained the fifth 
highest poverty rate in the nation.4 Even worse, Appalachian Kentucky has the highest 
poverty rate in the nation, at an astounding 1.7 times the national average. Of the 54 counties 
in Appalachia, 38 counties are economically distressed, or rank in the bottom 10% of all US 
counties.5
High poverty levels left a large portion of the Kentucky population uninsured and 
subsequently unable to seek preventative care.2,6-8 The Medicaid expansion of the Patient 
Protection and Affordable Care Act (ACA) was incredibly successful in reducing the 
uninsured rate in Kentucky.9 The expansion, enacted in 2014, provided Medicaid coverage 
to those at 138% of the federal poverty level (FPL). Being 1 of the first 2 states to implement 
the ACA, uninsured rates dropped in Kentucky by more than half, from 13.6% pre-ACA to 
6.1% 2 years post-ACA. At the same time, the national uninsured rate dropped from 14.7% 
to 9.4%. Medicaid expansion in the neighboring state of Illinois had a slightly smaller 
impact; its uninsured rate dropped from 12.9% to 7.0%. Conversely, Tennessee, a state that 
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did not expand Medicaid, experienced a modest decrease in the uninsured rate (from 13.8% 
to 10.2%). The population most affected by the expansion of Medicaid was those under 
138% of national poverty level, which demonstrated a nearly 3-fold drop in the rate of 
uninsured individuals (from 25.0% to 9.4%).10
When looking specifically at colorectal cancer (CRC), Kentucky ranks first nationwide for 
incidence (50.0 cases per 100,000) and fifth for mortality (17.2 deaths per 100,000).1,2 As 
expected, Appalachian Kentucky has an even higher incidence (55.1 cases per 100,000) and 
mortality (20.2 deaths per 100,000).2 Screening for CRC has been demonstrated to 
significantly decrease incidence and mortality.11,12 The US Preventative Services Task Force 
recommended screening for CRC beginning at the age of 50, with 1 of the following tests: 
high-sensitivity fecal occult blood testing annually, sigmoidoscopy every 5 years, or 
colonoscopy every 10 years.13 In the past, Kentucky has reported low rates of CRC 
screening. In 1999, only 34.7% of the Kentucky population received CRC screening of any 
type, ranking 49th in the nation.14 These results prompted several state-wide screening 
initiatives, including the establishment of the Kentucky Colon Cancer Screening Program 
and the Kentucky Colon Cancer Screening Advisory Committee in 2002. As a result, CRC 
screening rates improved to 65.9% in those 50 years old or older in 2012. However, CRC 
screening rates, although improved in western and central Kentucky, remained low in eastern 
Appalachian Kentucky.15,16 The purpose of this study was to evaluate the effect of ACA 
Medicaid expansion on CRC screening, incidence, and survival in the Kentucky population, 
with a particular focus on Appalachian Kentucky.
METHODS
Data sources
Kentucky CRC screening, incidence, and outcomes data were obtained from 2 distinct 
databases. Screening data on CRC were obtained from the Kentucky Hospital Discharge 
Database, which resided in the Kentucky Cabinet for Health and Family Services (KHFS). 
Ethical approval for the use of this database was obtained from the University of Kentucky’s 
Office of Research Integrity Institutional Review Board. The sample population included all 
patients older than 20 years who underwent CRC screening from January 1, 2011 to 
December 31, 2016. Each screening occurrence was captured through the CPT code 
involving either screening or diagnostic colonoscopy, sigmoidoscopy, guaiac-based fecal 
occult test, fecal immunochemical test, or fecal DNA test. Each case was then confirmed 
with the ICD (9 and 10) code for screening visits, allowing for the capture of recoded 
endoscopic procedures from screening to diagnostic due to positive findings.
Colorectal cancer demographics, incidence, and cancer outcomes data in the state of 
Kentucky were obtained through the Institutional Review Board-approved collaboration with 
the Kentucky Cancer Registry (KCR). A data use agreement was obtained between the 
investigator and KCR in April 2018. The KCR is a population-based registry and has been 
awarded the highest level of certification by the North American Association of Central 
Cancer Registries for an objective evaluation of completeness, accuracy, and timeliness 
every year since 1997. In addition, KCR is a National Cancer Institute Surveillance, 
Epidemiology, and End Results population-based cancer registry. The KCR also links its 
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database annually with the State Death Certificate data and National Death Index to capture 
the most accurate survival information.17 The study population included all patients 20 years 
and older, who were diagnosed with CRC between January 1, 2011 and December 31, 2016. 
Only the first invasive primary CRC was included in the analysis. Cases captured through 
autopsy or death certificates were excluded. Measures obtained include demographics (age 
at diagnosis, sex, race, metropolitan status, Appalachian status) and insurance coverage 
(Medicaid, Medicare, other public insurance, private insurance, and no insurance) based on 
payer information at the time of diagnosis from the KCR. Other variables of interest, such as 
socioeconomics (percentage below poverty status at the county level, high school education 
ascertainment at the county level) and clinical information (tumor grade, stage at diagnosis, 
and survival) were also included in the data analysis.
For the purpose of this study, the post-ACA implementation time period was defined as the 
implementation of Medicaid expansion on January 1, 2014, to December 31, 2016. The pre-
ACA period was defined as an equal length of time before ACA implementation from 
January 1, 2011 to December 31, 2013. County of residence at time of discharge from the 
KHFS or time of diagnosis from the KCR were used to define patients’ geographic regions. 
Metropolitan status was based on the 2013 Urban-Rural Continuum codes, with the values 
of 1 to 3 as urban and 4 to 9 as rural.18 The county-level Appalachian status was defined 
according to the Appalachia Regional Commission, as the 54 counties in Eastern Kentucky.5 
The 2008 to 2012 American Community Survey was used to create the poverty status and 
high school education ascertainment variables, which were collapsed into 4 levels based on 
the quartiles of their distributions. Poverty status was categorized as low (<16.2%), moderate 
(16.2% to 18.1%), high (18.2% to 21.7%), and very high (>21.7%); education ascertainment 
was categorized as very low (<75.8%), low (75.8% to 84.3%), moderate (84.4% to 88.0%), 
and high (88.1% to 91.8%). Stage at diagnosis was also categorized as early (stages I and II) 
and late stage (stages III and IV). Survival was defined as length of time from date of 
diagnosis to death or end of the study period.
Statistical analysis
Descriptive analysis was conducted for all variables. Chi-square tests were performed to 
examine the association between ACA status and other covariates, stratified by insurance 
status. Kaplan-Meier plots and log-rank tests were conducted by ACA status for each 
insurance type separately. Cox regression analysis was performed to determine whether 
ACA status is associated with survival while controlling for other variables, Goodness of fit 
and proportional hazard assumption were examined. Analyses were 2-sided with a p value ≤ 
0.05 used to identify statistical significance. All analyses were performed using SAS 
Statistical Software version 9.4 (SAS Institute, Inc).
RESULTS
Patient characteristics
A total of 930,176 patients were screened for CRC from 2011 to 2016. The highest 
proportion of patients screened was in 2015, and the lowest proportion screened was in 2011 
(Table 1). As expected, the highest proportion of those screened were in the ages 51 to 65 
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group. Interestingly, 8.2% of those screened were younger than 40 years old, which may be 
secondary to the high incidence of familial causes of CRC in Kentucky.19 More females 
were screened than males. The majority of patients who received screening were white 
(92.7%) and a small proportion were black (6.0%), which is slightly lower than the overall 
percentage of black patients in Kentucky (8.4%), demonstrating a screening disparity.20 
When looking at insurance coverage, nearly half of those screened had private insurance 
(47.8%), while 9.7% of patients had Medicaid and 1.4% were uninsured. About a fourth of 
the patients who received screening were Appalachian. When looking specifically at the 
Medicaid subgroup, higher proportions of female (62.6%) and black patients (9.6%) 
received screening compared with all insurance types. Nearly half of the Medicaid patients 
who received screening were Appalachian (42.3%).
Impact of Affordable Care Act expansion on colorectal cancer screening
A total of 408,500 patients were screened pre-ACA and 521,676 were screened after ACA 
implementation, an increase of 27.7% (Table 2). Colonoscopy was used as the major 
screening method in 72.7% of patients. The 51 to 65 years age group had the highest 
increase in screening, while both sexes increased proportionally. When comparing screening 
rates based on insurance coverage, patients with Medicaid demonstrated the highest increase 
in CRC screening. A total of 69,328 Medicaid patients received screening after ACA 
implementation compared with 20,980 individuals who were screened pre-ACA, 
representing an increase of 230%. Screening rates for patients with private insurance 
increased by 10.2% and Medicare patients increased by 29.9%. Overall, 43.7% more 
Appalachian patients received CRC screening after ACA implementation compared with 
pre-ACA.
When looking specifically at Medicaid patients, individuals in the 51 to 65 age group had 
the highest improvement in screening (+292.5%). There was also a higher proportional 
increase in screening in males compared with females after ACA implementation. The 
increase of coverage in all races remained proportional. Similar to the overall Kentucky 
trend, Medicaid coverage of Appalachian patients increased by 199.0% while uninsured 
Appalachian patients decreased by 77.7% after ACA implementation (Fig. 1).
Impact of Affordable Care Act expansion on colorectal cancer incidence
From January 1, 2011 to December 31, 2016, 11,441 Kentucky patients were diagnosed with 
CRC. After ACA Medicaid expansion, there was not a significant increase in incidence 
(5,665 pre-ACA vs 5,776 after ACA implementation), but there was a change in the 
distribution (Table 3). The CRC incidence in the 20 to 49 age group increased by 22.8%, 
while the age 75 to 90 group decreased by 7.5%, indicating a shift toward an increase in 
incidence in the younger population consistent with national CRC trends.21 When separated 
by insurance, the proportion of Medicaid patients who were diagnosed with CRC increased 
by 132.4% after Medicaid expansion. In patients who had Medicaid, there were no 
significant differences in regard to poverty and education level, indicating a similar 
population before and after ACA implementation. Consequently, there was a 4-fold decrease 
in incidence in the uninsured group.
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When evaluating patients who had Medicaid coverage, there was an increase in Appalachian 
CRC incidence (87.8%) (Fig. 2). When separating out incidence by stage in this group, the 
proportion of early stage diagnoses (stage I/II) increased by 9.3% for Appalachians (p = 
0.09), which was not noted in non-Appalachians (−1.5%, p = 0.60). There was no effect on 
late stage diagnosis.
Impact of Affordable Care Act expansion on colorectal cancer survival
When evaluating the role of ACA expansion in CRC survival, both Medicaid and 
Appalachian patients benefited while uninsured patients suffered. After ACA 
implementation, Medicaid patients exhibited improved survival compared with patients 
before instituting ACA (Fig. 3). Conversely, the remaining uninsured patients who did not 
receive coverage from ACA implementation had a worse survival compared to pre-ACA 
implementation. There were no significant differences in survival for private insurance and 
Medicare with regard to ACA expansion. Notably, the survival differences after ACA 
implementation were evident in Medicaid patients after the first year and increased each year 
thereafter (eTable 1). We noted an overall worse survival (hazard ratio [HR] 2.12, 95% CI 
1.23 to 3.67, p = 0.048) in the black uninsured population compared with the white 
population, consistent with national trends.22 This effect was not seen in any other insurance 
groups.
When controlling for age, sex, race, cancer stage, and grade, Cox regression analysis 
revealed that all Medicaid patients had improved survival after ACA implementation 
compared with pre-ACA implementation (HR 0.73, 95% CI 0.58 to 2.11; p = 0.008). 
Interestingly, when looking specifically at Appalachian patients with Medicaid coverage, 
there was significantly improved survival after ACA implementation compared with the 
period pre-ACA (Fig. 4). However, there was no difference in survival in the Medicaid non-
Appalachian population, indicating the improvement in overall Medicaid patient survival 
after ACA implementation was heavily contributed by the Appalachian population.
DISCUSSION
The ACA Medicaid expansion has had unprecedented success in providing Medicaid 
coverage for the uninsured population in Kentucky. Earlier studies demonstrated that 
implementation of the expansion increased screening in prostate cancer,23 cervical cancer,
24-26
 and breast cancer.25,27 In Kentucky, improved coverage was also associated with earlier 
diagnosis of breast cancer and improved treatment quality.27 We set out to evaluate the 
impact of ACA expansion on CRC screening. We found the expansion of Medicaid in 
Kentucky significantly increased CRC screening, particularly in the Appalachian population. 
Moreover, ACA expansion was associated with increased CRC incidence in the Medicaid 
population with a shift toward early stage diagnosis in Appalachian patients. Importantly, we 
demonstrated for the first time that ACA expansion significantly increased CRC survival in 
both the Medicaid and Kentucky Appalachian populations.
Our study established the substantial impact of insurance coverage in amplifying CRC 
screening. Over the past 2 decades, Kentucky has implemented several programs to expand 
CRC screening.15 The major barriers to CRC screening include lack of insurance coverage 
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and lack of provider recommendation.6-8,28,29 Our study demonstrated that the ACA 
Medicaid expansion decreased the number of low-income uninsured patients in Kentucky, 
helping to alleviate barriers to health care access. By 2015, in the second year of expansion, 
there was 12% increased access to primary care physicians, allowing more than 85% of low-
income patients to easily obtain physician visits.30 Improved health care system contact led 
to increased preventative screening by enabling access to primary care physicians.9 The 
Behavioral Risk Factor Surveillance System reported in 1999 that the CRC screening rate in 
Kentucky was 34.7% compared with 43.9% nationally. Screening for CRC plateaued just 
before ACA implementation, at 65.7%. After ACA implementation in 2014, screening in 
Kentucky further increased to 69.6% compared with 66.6% nationally.14,31 However, 
Appalachian Kentucky screening lagged behind, at 63.0%.2 The most recent 2016 data 
revealed further improvement of screening rates to 70.1% compared with 67.7% nationally.
14,31
 Similarly, we identified a larger than 3-fold increase in CRC screening 3 years after 
Medicaid expansion.
In Kentucky, additional insurance coverage increased CRC incidence immediately after 
ACA implementation. The incidence of CRC has steadily decreased over the past 40 years.
32,33
 Microsimulation models suggest the largest contribution comes from screening, while 
risk factor reduction and treatment improvements are minor contributors.33,34 Early 
detection of precursor lesions would have immediate reduction of CRC incidence within the 
first 2 years and maximal reduction by 15 years.32,34-38 We would expect an immediate 
increased incidence in newly insured Medicaid patients as existing cancers are identified. In 
addition, this population may also have a shift toward earlier stage diagnosis.39,40 However, 
as expected, the removal of pre-cancerous lesions would decrease cancer progression, 
leading to decreased incidence rates.11 Similarly, we identified an increase of incidence in 
the Medicaid and Appalachian population immediately after ACA implementation. We 
demonstrated a trend toward higher rates of early stage (I and II) CRC diagnosis in the 
Appalachian population, which was not seen in the uninsured population. Because this study 
evaluated the short-term effects of Medicaid expansion, we would not expect a decrease in 
CRC incidence.
Screening for CRC is very effective in reducing the cancer-specific mortality risk. Zauber 
and colleagues12 demonstrated a 53% reduction of 10-year survival in patients who received 
a screening colonoscopy. In fact, the impact of CRC screening on survival continues for up 
to 2 decades.41 Even so, CRC mortality in Kentucky remain behind national standards. In 
2011 to 2015, the mortality rate of CRC nationally was 14.5 per 100,000 compared with 
17.0 per 100,000 in the state of Kentucky.2 Appalachian Kentucky mortality was even 
higher, with a more profound benefit from screening.42,43 In just a short time interval after 
ACA implementation, we showed that Medicaid patients had a 27% lower risk of death 
compared with pre-ACA, while those who were uninsured had an overall worse survival. 
Notably, the Kentucky Appalachian patients also had a significantly improved survival 
associated with the dramatic expansion of Medicaid coverage as a result of increased CRC 
screening.
We demonstrated a markedly improved survival in both the Medicaid and Kentucky 
Appalachian population in just a short time after ACA implementation. In fact, the 
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significant survival improvement was evident within the first year. Similarly, several studies 
including a large meta-analysis demonstrated a survival difference at 3 years after receiving 
CRC screening, with the maximal effect at 15 years.44,45 The short-term effects of a CRC 
screening program implementation on survival was also found in a Kaiser Permanente health 
system, demonstrating a significant decrease in mortality within 4 years.11 Our survival 
follow-up time was greater than 6 years for the pre-ACA group and greater than 4 years for 
the after ACA implementation group. Because CRC incidence can drop within 2 years after 
improved screening, survival differences can be seen within our follow-up time period, 
partly due to early detection and treatment.35 Importantly, the improved survival after ACA 
implementation was not evident in the private, Medicare, and uninsured populations, 
indicating the specific association of survival after CRC screening with Medicaid patients.
The results of this study could be generalized to other states that have expanded Medicaid 
coverage. Nonetheless, there are several limitations to this study. The CRC screening data 
may contain a small number of patients who underwent more than 1 screening procedure, so 
were counted twice. However, it is extremely unlikely for a second procedure to be coded as 
a screening procedure, and more likely to be coded as a diagnostic procedure. In addition, 
before 2016, post-hoc manipulation of CPT codes was legal. As a result, there may be a bias 
among the colonoscopies that had CPT codes converted from screening to diagnostic as a 
result of a positive finding during the procedure. This would have underestimated screening 
colonoscopies before 2016. Next, the significant survival benefit identified in the Medicaid 
population after ACA implementation may be contributed by other factors that were not 
included in the analysis. For example, before ACA implementation, only the most 
impoverished adults (less than half of FPL) were covered by Medicaid. After 
implementation, the coverage included up to 138% of the FPL. This higher income group 
was likely more health conscious and had better access to care, which was evident by the 
decreased survival in the uninsured population, suggesting that only patients with the lowest 
level of access remain uninsured after ACA implementation. However, these individual 
socioeconomic and health access factors were not available for the data analysis. Last, 
cancer survival is also related to reliable quality treatment, which is not accounted for in our 
survival analysis. However, due to our demonstration of improvement in survival post-ACA, 
poor quality treatment would unlikely effect our results negatively.
CONCLUSIONS
The incidence and mortality of colorectal cancer in Kentucky are among the highest in the 
United States. Affordable Care Act Medicaid expansion has positively affected insurance 
coverage in this population, leading to improved CRC screening and improved short-term 
survival. Future long-term survival studies are needed, but the short-term benefits of the 
ACA expansion have bridged a gap in CRC disparities in Kentucky.
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Extended Data
eTable 1.
Lifetable by Insurance Status
Pre-ACA Post-ACA
Insurance, y Surviving 95% CI Surviving 95% CI p Value
Private 0.7877
 0 1.000 – 1.000 –
 1 0.900 (0.886–0.914) 0.903 (0.888–0.916)
 2 0.820 (0.803–0.839) 0.826 (0.805–0.844)
 3 0.764 (0.744–0.784) 0.764 (0.736–0.789)
Medicare 0.1980
 0 1.000 – 1.000 –
 1 0.753 (0.738–0.768) 0.755 (0.739–0.771)
 2 0.658 (0.641–0.675) 0.631 (0.612–0.650)
 3 0.579 (0.561–0.596) 0.552 (0.528–0.575)
Medicaid 0.0024
 0 1.000 – 1.000 –
 1 0.779 (0.727–0.822) 0.838 (0.807–0.864)
 2 0.641 (0.584–0.693) 0.739 (0.700–0.773)
 3 0.570 (0.511–0.624) 0.662 (0.613–0.707)
Uninsured 0.0335
 0 1.000 – 1.000 –
 1 0.841 (0.795–0.877) 0.695 (0.560–0.796)
 2 0.733 (0.679–0.779) 0.620 (0.475–0.736)
 3 0.647 (0.590–0.697) 0.540 (0.376–0.679)
ACA, Affordable Care Act.
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KCR Kentucky Cancer Registry
KHFS Kentucky Cabinet for Health and Family Services
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Figure 1. 
Colorectal cancer (CRC) screening by insurance and Appalachian (App) status. Colorectal 
cancer screening data were obtained from the Kentucky Cabinet for Health and Family 
Services from January 1, 2011 to December 31, 2016. (A) All screening cases were 
separated by insurance status depending on pre-Affordable Care Act (ACA) (screening 
obtained in 2011 to 2013) or post-ACA status (screening obtained in 2013-2016). (B) 
Patients with Medicaid coverage who received screening were separated by Appalachian and 
non-Appalachian status and compared pre- and post-ACA implementation.
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Figure 2. 
Colorectal cancer (CRC) incidence by insurance and Appalachian (App) status. The CRC 
incidence from January 1, 2011 to December 31, 2016 was obtained from the Kentucky 
Cancer Registry. Pre-ACA was defined as the time period from 2011 to 2013 while post-
ACA was from 2014 to 2016. (A) All cases of CRC were separated out by insurance types 
and compared before and after ACA implementation. (B) Incidence rates of CRC were 
compared in all Medicaid patients separated by Appalachian and non-Appalachian status.
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Figure 3. 
Colorectal cancer (CRC) survival after Affordable Care Act (ACA) by insurance type. 
Survival analysis was performed via Kaplan-Meier plots. Pre-ACA was defined as the time 
period between 2011 and 2013, and post-ACA was defined as the time period between 2014 
and 2016. All CRC cases were separated by insurance status: (A) private; (B) Medicaid; (C) 
Medicare; and (D) no insurance.
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Figure 4. 
Colorectal cancer (CRC) survival for Medicaid patients after Affordable Care Act (ACA) by 
Appalachian status. Medicaid patients who were diagnosed with CRC were identified in the 
Kentucky Cancer Registry from January 1, 2011 to December 31, 2016. Survival analysis 
was performed with Kaplan-Meier plots to evaluate survival in the (A) non-Appalachian and 
(B) Appalachian population.
Gan et al. Page 16
J Am Coll Surg. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gan et al. Page 17
Table 1.
Patient Demographics
Patient characteristic n %
All Kentucky patients, 2011–2016, n = 930,176
ACA Status
 Pre-ACA* 408,500 43.9
 Post-ACA 521,676 56.1
Year screened
 2011 124,049 13.3
 2012 142,166 15.3
 2013 142,285 15.3
 2014 151,956 16.3
 2015 194,406 20.9
 2016 175,314 18.9
Age
 20–40 y 75,923 8.2
 41–50 y 129,050 13.9
 51–65 y 422,588 45.4
 66–70 y 118,714 12.8
 >71 y 183,901 19.8
Sex
 Female 517,830 55.7
 Male 412,346 44.3
Race
 White 862,144 92.7
 Black 55,742 6.0
 Other 12,290 1.3
Insurance
 Not insured 14,064 1.5
 Private 444,794 47.8
 Medicare 367,974 39.6
 Medicaid 90,308 9.7
 Other public† 13,036 1.4
Stage
 I 2,444 21.8
 II 2,600 23.2
 III 2,789 24.9
 IV 2,224 19.8
 Unknown 1,152 10.3
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Patient characteristic n %
Appalachian status
 Non-Appalachian 682,545 73.4
 Appalachian 247,631 26.6
Medicaid patients only, 2011–2016, n = 90,308
ACA Status
 Pre-ACA* 20,980 23.2
 Post-ACA 69,328 76.8
Year screened
 2011 6,606 733
 2012 7,282 8.1
 2013 7,092 7.8
 2014 20,394 22.6
 2015 27,772 30.8
 2016 21,162 23.4
Age
 20–40 y 19,762 21.9
 41–50 y 21,052 23.3
 51–65 y 48,151 53.3
 66–70 y 664 0.7
 >71 y 679 0.8
Sex
 Female 56,510 62.6
 Male 33,798 37.4
Race
 White 79,798 88.4
 Black 8,661 9.6
 Other 1,849 2.0
Appalachian status
 Non-Appalachian 52,112 57.7
 Appalachian 38,196 42.3
Stage
 I 195 19.7
 II 207 20.9
 III 237 24.0
 IV 255 25.8
 Unknown 95 9.6
*
Pre-Affordable Care Act (ACA) from 2011 to 2013; post-ACA from 2014-2016.
†
Includes TRICARE, Veterans Affairs, and military insurances.
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